<DOC>
	<DOCNO>NCT00576602</DOCNO>
	<brief_summary>This 2 arm study ass efficacy , safety tolerability subcutaneous Mircera , versus ESA therapy , chronic kidney disease patient anemia kidney transplant , currently treat ESA . Patients randomized receive ) subcutaneous Mircera recommend start dose 0.6 micrograms/kg every 2 week , switch monthly treatment week 16 b ) supportive treatment ( eg . iron supplementation ) management low hemoglobin concentration . The anticipated time study treatment 3-12 month , target sample size 100-500 individual .</brief_summary>
	<brief_title>A Study Subcutaneous Mircera , Versus Erythropoiesis-Stimulating Agent ( ESA ) Therapy , Treatment Anemia Patients With Chronic Kidney Disease After Kidney Transplant</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Hematinics</mesh_term>
	<criteria>adult patient , &gt; =18 year age ; kidney transplant &gt; =6 month &lt; 5 year prior randomization ; anemia ; ESA therapy 3 month prior randomization . requirement hemodialysis peritoneal dialysis within 3 month prior randomization ; change Hb concentration &gt; =1.5g/dL screen period ; transfusion red blood cell 3 month prior randomization ; poorly control hypertension ; significant acute chronic bleeding within 3 month prior randomization .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>